The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index; 50 of the 77 sources its claims cite were checked for support.
Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications
Open accessAbstract
Background/Objectives: Regenerative therapies have gained interest in orthopedic applications for their potential to enhance tissue regeneration, functional recovery, and pain modification. This review evaluates the clinical efficacy of platelet-rich plasma (PRP), mesenchymal stem cells (MSCs), peptide-based treatments, and biomimetic materials in orthopedic care, with a focus on pain reduction and functional outcomes. Methods: A structured literature search in PubMed (January 2009–January 2025) identified 160 studies. After applying inclusion criteria prioritizing randomized controlled trials (RCTs) and clinical trials, 59 studies were included: 20 on PRP, 20 on MSCs, 10 on peptide therapies, and 7 on biomimetics. Data extraction focused on pain reduction and functional recovery, with risk of bias assessed using the Cochrane Risk of Bias (RoB) tool and ROBINS-I tool. A random-effects meta-regression analysis was conducted to evaluate the impact of therapy type, sample size, and risk of bias on reported pain reduction outcomes. Results: Meta-regression analysis identified MSC therapy as the most effective intervention for pain reduction (β = 8.45, p < 0.05), with PRP and peptide-based therapies showing moderate improvements, and biomimetic therapies demonstrating the lowest effect. PRP provided short-term pain relief, particularly in acute injuries and tendon repair, though inconsistencies in preparation methods limited success in chronic conditions. MSC therapies demonstrated cartilage regeneration and early osteoarthritis improvement, but high costs and ethical concerns remain barriers to widespread adoption. Peptide-based therapies and biomimetic materials, including engineered scaffolds and autologous protein solutions, showed promise for infection control and wound healing, though further research is needed to optimize dosing, delivery methods, and long-term safety. Conclusions: Regenerative therapies offer significant potential in orthopedic care, with MSC therapies demonstrating the most reliable regenerative effects, PRP providing short-term symptomatic relief, and peptide-based and biomimetic treatments emerging as promising adjuncts. However, standardized protocols and large-scale clinical trials are needed to establish long-term efficacy and improve clinical translation for broader adoption.
Overview
CoChat Summary
TL;DR
This review compares clinical evidence for PRP, mesenchymal stem cells (MSCs), peptide therapies, and biomimetic materials in orthopedic care, focusing on pain reduction and functional recovery. Across 59 included studies, MSCs showed the strongest pain-reduction signal, while PRP tended to provide short-term relief and peptide/biomimetic approaches remained promising but less established.
Key findings
- The PubMed search (January 2009–January 2025) identified 160 studies, and 59 studies met inclusion criteria: 20 PRP, 20 MSC, 10 peptide, and 7 biomimetic studies.
- Mean reported pain reduction was highest for MSC therapy (45.05 ± 3.85%), followed by PRP (41.00 ± 6.36%), biomimetic therapies (37.43 ± 2.82%), and peptide therapies (35.50 ± 3.03%).
- Welch’s ANOVA showed a significant difference in pain reduction across therapy types (F(3, 43) = 13.31, p < 0.001). Games–Howell tests found stem cell therapy had significantly greater pain reduction than peptides, PRP, and biomimetics (all p < 0.001).
- Meta-regression found therapy type significantly influenced pain reduction (QM(df = 3) = 14.15, p < 0.05); sample size and risk of bias were not significant predictors, and residual heterogeneity remained high (I² = 81.13%).
Methods
- This was a comprehensive review of clinical orthopedic studies on PRP, MSCs, peptide therapies, and biomimetic materials, using a PRISMA-guided PubMed search from January 2009 to January 2025.
- Inclusion prioritized clinical trials and randomized controlled trials; studies had to report orthopedic outcomes such as pain reduction, functional recovery, infection rates, healing time, or quality-of-life measures. Preclinical, non-English, or otherwise ineligible studies were excluded.
- Risk of bias was assessed with the Cochrane RoB tool and ROBINS-I. The authors then conducted a random-effects meta-regression (REML) plus one-way ANOVA/Welch’s ANOVA and Games–Howell post hoc tests in R 4.4.2.
Limitations
- The paper states that 10 studies were omitted from the pain-reduction analysis because that outcome was missing or unreported; it notes this was most common in PRP studies.
- The review reports substantial residual heterogeneity (I² = 81.13%), meaning important study-level factors likely remained unmeasured.
- Many included studies were single-center with small sample sizes, limiting generalizability; the paper also notes heterogeneity in PRP preparation, MSC sourcing, and peptide dosing, and limited long-term follow-up.
- Evident from the text: the quantitative synthesis focused on pain reduction, so conclusions about broader outcomes like function, durability, or safety are less directly supported by the pooled analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
33 Valid · 9 Not valid · 16 Not checked · 58 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“PRP also appears to have limited benefit in certain conditions, such as Achilles tendinopathy and knee osteoarthritis, where trials have reported no significant improvement over placebo [109].”
§ Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications > 4. Discussion > 4.1. Platelet-Rich Plasma (PRP)
What the sources say
- Disputedcites [109] Pojala, 2024, The potential of intra-articular therapies in managing knee osteoarthritis: A systematic review, Clin. Pract. sourceExperimental — accuracy not yet measured
The Results (§3.3; page unavailable) describe substantial improvements in pain and function with PRP for knee osteoarthritis, and the Discussion (§4.2; page unavailable) reports benefits over hyaluronic acid. This runs contrary to the claim of limited benefit for knee osteoarthritis, although the review does not establish the specific placebo comparison. The retrieved passages do not address Achilles tendinopathy. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Traditionally, treatments such as surgical repair, physical therapy, and pharmaceutical interventions have been employed to address these conditions, but they frequently result in variable outcomes and inconsistent recovery periods [1].”
§ Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications > 1. Introduction
What the sources say
- Could not verifycites [1] Choi, 2022, Enhanced Recovery After Surgery for Major Orthopedic Surgery: A Narrative Review, Knee Surg. Relat. Res. sourceExperimental — accuracy not yet measured
The Outcomes of ERAS section (LOS; page unavailable) reports shorter hospital stays with ERAS than with control or non-ERAS care. The Multimodal and standardized care system section (page unavailable) recommends standardized pathways, but neither passage says that surgical repair, physical therapy, and pharmaceutical interventions frequently produce variable outcomes or inconsistent recovery periods. Searches for traditional treatments and recovery variability found no passage establishing that claim. (LLM, conf=0.73)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Peptide-based therapies, which encompass antimicrobial peptides and growth factors, are particularly appealing for their dual ability to combat infection and promote healing [23,24].”
§ Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications > 1. Introduction
What the sources say
- Partly supportedcites [23] Zarghami, 2021, Prevention of biofilm formation on orthopedic implants by melittin thin layer on chitosan/bioactive glass/vancomycin coatings, J. Mater. Sci. Mater. Med. sourceExperimental — accuracy not yet measured
The Abstract reports that melittin, an antimicrobial peptide, increased MC3T3 cell proliferation and that coatings combining melittin with vancomycin eliminated MRSA and VRSA bacteria. This supports infection control and a healing-related cellular effect in this specific implant coating, but the paper does not establish that peptide-based therapies generally, including growth factors, both combat infection and promote healing. (LLM, conf=0.86)
- Partly supportedcites [24] Park, 2011, The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation, Int. J. Mol. Sci. sourceExperimental — accuracy not yet measured
The Introduction describes antimicrobial peptides as potential alternatives to antibiotics, and the Conclusions say they may combat multidrug-resistant and biofilm-forming infections. The passages do not establish that these peptides promote healing or discuss growth factors as part of a dual infection-and-healing therapy. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, MSC-based therapies, particularly those utilizing MSCs derived from bone marrow, adipose tissue, or umbilical cord blood, offer substantial regenerative potential due to their ability to differentiate into various tissue types and modulate immune responses [17,18].”
§ Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [17] Dominici, 2006, Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, Cytotherapy source
- Partly supportedcites [18] Zampogna, 2024, Safety and efficacy of autologous adipose-derived stem cells for knee osteoarthritis in the elderly population: A systematic review, J. Clin. Orthop. Trauma. sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says MSCs can differentiate into chondrocytes and describes cytokines and growth factors that may promote cartilage repair. This supports regenerative potential, particularly for adipose-derived MSCs, but the paper does not establish immune-response modulation or the same potential for umbilical-cord-blood-derived MSCs. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Additionally, growth factor-derived peptides have been explored as adjunct therapies to PRP, demonstrating enhanced wound healing and tendon regeneration [101,102].”
§ Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications > 3. Results > 3.3. Peptide Therapies
What the sources say
- Not checked — no full text of the sourcecites [101] Pugliese, 2017, Peptidic Biomaterials: From Self-Assembling to Regenerative Medicine, Trends Biotechnol. source
- Could not verifycites [102] Hao, Z., Chen, R., Chai, C., Wang, Y., Chen, T., Li, H., Hu, Y., Feng, Q., and Li, J. (2022). Antimicrobial Peptides for Bone Tissue Engineering: Diversity, Effects, and Applications. Front. Bioeng. Biotechnol., 10. sourceExperimental — accuracy not yet measured
The Introduction discusses antimicrobial peptides in wound repair, and §3.4 discusses their regenerative effects in bone tissue engineering. Neither passage addresses growth factor-derived peptides used alongside PRP or an effect on tendon regeneration. Searches for PRP, tendon, and growth factor-derived peptides found no passage establishing the attributed claim. (LLM, conf=0.76)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
62 more claims · 13 with their cited sources checked
Create a free account to see all 116 claims and to verify the 11 references still open.
- It may state two separate claims as one. 47
- Probably not a substantial claim. 3
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- ConsistentF(3, 43) = 3.64reported p < .05 · recomputed p = .020
“F(3, 43) = 3.64, p < .05”
- ConsistentF(3, 43) = 13.31reported p < .001 · recomputed p < .001
“F(3, 43) = 13.31, p < .001”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications > Abstract
“After applying inclusion criteria prioritizing randomized controlled trials (RCTs) and clinical trials, 59 studies were included: 20 on PRP, 20 on MSCs, 10 on peptide therapies, and 7 on biomimetics.”
§ Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications > 2. Methods > 2.4. Statistical Analysis
“The final dataset included 20 PRP studies, 20 stem cell studies, 10 peptide studies, and 7 biomimetic studies.”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329 · cited 1×
“The risk of bias assessment was conducted using the Cochrane Risk of Bias tool for randomized controlled trials and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool for non-randomized and observational studies [35,36].”
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766 · cited 1×
“Similarly, MSC-based therapies, particularly those utilizing MSCs derived from bone marrow, adipose tissue, or umbilical cord blood, offer substantial regenerative potential due to their ability to differentiate into various tissue types and modulate immune responses [17,18].”
Antimicrobial peptides of multicellular organisms
Zasloff, M. (2002) · Nature · doi:10.1038/415389a · Cited by 8,457 · cited 2×
“Orthopedic surgery often involves managing complex musculoskeletal injuries and degenerative conditions that pose challenges in achieving complete functional recovery. tissue regeneration [25,26].”
Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies
Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., Benhaim, P., Lorenz, H. P., & Hedrick, M. H. (2001) · Tissue Engineering · doi:10.1089/107632701300062859 · Cited by 7,956
Biomaterials & scaffolds for tissue engineering
O'Brien, F. J. (2011) · Materials Today · doi:10.1016/s1369-7021(11)70058-x · Cited by 3,437 · cited 2×
“2 of 23 Biomimetic materials, including engineered scaffolds and autologous protein solutions, represent an emerging class of regenerative therapies aimed at mimicking natural tissue environments to facilitate healing and integration [28,29].”
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131 · cited 1×
“Peptides integrated into bioactive scaffolds show potential for infection con-trol and tissue regeneration, yet clinical translation remains limited [127,128].”
Mesenchymal stem cell perspective: cell biology to clinical progress
Pittenger, M. F., Discher, D. E., Péault, B. M., Phinney, D. G., Hare, J. M., & Caplan, A. I. (2019) · npj Regenerative Medicine · doi:10.1038/s41536-019-0083-6 · Cited by 2,008 · cited 1×
“Clinical applications of MSCs in cartilage repair, early-stage osteoarthritis, and fracture healing have shown encouraging results, especially in early degenerative conditions [19–21].”
Platelet-Rich Plasma (PRP): What Is PRP and What Is Not PRP?
Marx, R. E. (2001) · Implant Dentistry · doi:10.1097/00008505-200110000-00002 · Cited by 1,704
Research works printed but not linked: 1
- Chaudhary, 2024, Emerging trends in PRP and MSC-based therapies: A review of clinical efficacy and limitations, Int. J. Musculoskelet. Med., 12, 85
Cited by
Aithal, A. (2025) · Poornaprajna International Journal of Basic & Applied Sciences (PIJBAS) · doi:10.64818/pijbas.3107.8478.0017 · Cited by 6
Cavallo, C., Desando, G., D’Alessandro, M., Grigolo, B., & Roseti, L. (2025) · Gels · doi:10.3390/gels11070551 · Cited by 8
“Long-term clinical results are still needed to support the use of those strategies [108].”
Pham, G. M.-T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196959 · Cited by 10
“Hybrid constructs combining multiple strategies such as scaffold + PRP + exosome or scaffold + BMAC + peptide are also being tested to optimize the healing microenvironment [8,26].”
Kim, S.-H., Lee, U., Yoon, Y., et al. (2026) · Bioengineering · doi:10.3390/bioengineering13040418 · Cited by 3
“Regenerative approaches—including prolotherapy, platelet‑rich plasma (PRP), and cell‑based therapies— aim to stimulate collagen remodeling and structural reinforcement at sites of ligamen‑ tous or enthesis‑level pathology [15–18].”
Platelet rich plasma applications in orthopedics: A review of recent advances
Rathod, A. P., Rathod, Y., Baitule, R. W., Pundkar, G. N., & Saodekar, H. (2025) · World Journal of Orthopedics · doi:10.5312/wjo.v16.i12.110377 · Cited by 5
Metadata
- Authors
- Goulian, A. J., Goldstein, B., & Saad, M. A.
- Affiliations
- California Northstate University (US)
- Department of Orthopaedic Surgery, University of California, Sacramento, CA 95817, USA
- Corresponding author
- Saad, Maarouf A.
- ORCID
- Goulian, Andrew J.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2025-03-18
- Volume
- 14
- Issue
- 6
- Pages
- 2061
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC11943164
- OpenAlex
- W4408551393
- Cited by
- 25
- References
- 136
- Citations by year
- 2026: 14 · 2025: 11
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Dentistry › Periodontics › Periodontal Regeneration and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Tendon Structure and Treatment
- Keywords
- regenerative therapy, orthopedics, platelet-rich plasma, mesenchymal stem cells, peptide therapy, biomimetic materials, analgesia, functional recovery, cartilage regeneration, osteoarthritis, engineered scaffolds, wound healing, infection control, tendon repair
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications. https://app.cochat.ai/papers/10.3390/jcm14062061
- The paper
- Goulian, A. J., Goldstein, B., & Saad, M. A. (2025). Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications. Journal of Clinical Medicine. https://doi.org/10.3390/jcm14062061
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.